INTERNATIONAL SEARCH REPORT

International application No PCT/EP2007/058453

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K31/185 A61K3 A61K31/216 A61K31/222 A61K31/255 A61K31/192 A61K45/06 A61P35/02 A61P35/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, WPI Data, EMBASE, BIOSIS C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category* 1,3-7,9, US 6 231 880 B1 (PERRINE SUSAN P [US]) 10,12-15 15 May 2001 (2001-05-15) column 10, paragraph 6 column 12, paragraph 2 claim 2 column 25, paragraph 3 1,3-7,9, KAWADA M ET AL: "INHIBITION OF ABELSON 10,12-15 ONCOGENE FUNCTION BY ERBSTATIN ANALOGUES" DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, BIOSCIENCE EDIPRINT INC, vol. 19, no. 6, 1993, pages 235-241, XP000569615 ISSN: 0378-6501 abstract Further documents are listed in the continuation of Box C. See patent family annex. * Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but *A* document defining the general state of the art which is not cited to understand the principle or theory underlying the considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *L* document which may throw doubts on priority claim(s) or "Y" document of particular relevance; the claimed invention which is cited to establish the publication date of another citation or other special reason (as specified) cannot be considered to involve an inventive step when the document is combined with one or more other such docu-O document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled other means in the art. "P" document published prior to the international filing date but "&" document member of the same patent family later than the priority date claimed Date of mailing of the international search report Date of the actual completion of the international search 15/07/2008 10 March 2008 **Authorized officer** Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Strack, Eberhard Fax: (+31-70) 340-3016

INTERNATIONAL SEARCH REPORT

International application No PCT/EP2007/058453

	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	WO 93/07866 A (SAMID DVORIT [US]) 29 April 1993 (1993-04-29) page 56, paragraph 2	1,3-7,9, 10,12-15
` .	CUEVAS P ET AL: "Dobesilate is an angiogenesis inhibitor" EUROPEAN JOURNAL OF MEDICAL RESEARCH 12 SEP 2005 GERMANY, vol. 10, no. 9, 12 September 2005 (2005-09-12), pages	1,3-7,9, 10,12-15
	369-372, XP008088025 ISSN: 0949-2321 abstract	
	SIMIZU SIRO ET AL: "Induction of Apoptosis by Erbstatin in Mouse Leukemia L1210 Cells"	1,3-7,9, 10,12-15
	BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 58, no. 9, 1994, pages 1549-1552, XP008088070 ISSN: 0916-8451 abstract	
	YAMADA, KATSUHISA ET AL: "Inhibitory effect of diacetyl gentisic acid on melanogenesis" NIPPON KOSHOHIN KAGAKKAISHI, 22(3), 169-174 CODEN: NKKAEV; ISSN: 0287-1238, 1998, XP008088000 abstract	
		· · · · · · · · · · · · · · · · · · ·

International application No. PCT/EP2007/058453

INTERNATIONAL SEARCH REPORT

Box No. II Observations where certain claims were round unsearchable (Continuation of Item 2 of mot sheet)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 15 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of
additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search reportcovers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
see annex
Remark on Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 3-7, 9-10, 12-15 (partially)

Use of a compound of Formula (I^{\prime}) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of leukemia and other hematological dyscrasias

2. claims: 1, 3-7, 9-10, 12-15 (partially)

Use of a compound of Formula (I') or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy

3. claims: 2, 8, 11, 16, 17 (completely); 3-6, 9, 10, 12-14 (partially)

Use of a compound of Formula $(I^{\prime\prime})$ or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of cancer of an organ

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2007/058453

Patent document cited in search report		Publication date	·	Patent family member(s)	Publication date
US 6231880	B1	15-05-2001	US	2001027215 A1	04-10-2001
WO 9307866	Α	29-04-1993	AU CA EP ZA	2804592 A 2108963 A1 0567613 A1 9208140 A	21-05-1993 22-04-1995 03-11-1993 21-04-1994